ALDOB and hepatocellular carcinoma: Yin et al. found that in liver cancer, downregulation of ALDOB, by interacting with KAT2A, suppresses TGF-β expression, which in turn impairs the functionality of CD8+ T cells, promoting tumor immune escape and progression of HCC 202.